Analysis of the efficacy of ursodesoxycholic acid combined with adenosylmethionine butanedisulfonate for treating pregnant women with chronic hepatitis B and intrahepatic cholestasis in pregnancy and the factors influencing the adverse pregnancy outcomes
Analysis of the efficacy of ursodesoxycholic acid combined with adenosylmethionine butanedisulfonate for treating pregnant women with chronic hepatitis B and intrahepatic cholestasis in pregnancy and the factors influencing the adverse pregnancy outcomes
Objective:To investigate the efficacy of ursodesoxycholic acid(UDCA)combined with adenosylmethionine butanedisulfonate(SAMe)for treating pregnant women with chronic hepatitis B and intrahepatic cholestasis in preg-nancy(ICP),and to study the factors influencing the adverse pregnancy outcomes of the women.Methods:86 preg-nant women with chronic hepatitis B and ICP were selected and were divided into two groups according to the different treatment methods from June 2020 to June 2023.40 women in the study group were treated with UDCA combined with SAMe,while 46 women in the control group were treated with single-agent UDCA.The clinical efficacy of the women was compared between the two groups.The levels of liver function indexes,such as aspartate aminotransferase(AST),alanine aminotransferase(ALT)and serum total bilirubin(TBIL),of the women in the two groups were de-tected,and the influence of which on the pregnancy outcomes of the women were analyzed.Results:The total clinical efficacy rate(92.5％)of the women in the study group was significantly higher than that(76.1％)of the women in the control group(P＜0.05).The liver function-related indexes levels of the women in the two groups after treatment had improved significantly,and which of the women in the study group were significantly better than those of the women in the control group(all P＜0.05).There was no significant difference in the incidence of the adverse reactions(5.0％vs.4.3％)of the women after treatment between the two groups(P＞0.05).The incidence of the adverse pregnancy out-comes(7.5％)of the women in the study group was significantly lower than that(23.9％)of the women in the control group(P＜0.05).Multivariate logistic regression analysis showed that the elevations of the levels of liver function in-dexes,such as ALT,AST and HbsAg,of the pregnant women with chronic hepatitis B and ICP were all the independ-ent risk factors of their adverse cy outcomes(P＜0.05).Conclusion:UDCA combined with SAMe for treating the pregnant women with chronic hepatitis B and ICP has better efficacy,and without increase the side effect.The high levels of ALT,AST and HbsAg of the pregnant women with chronic hepatitis B and ICP are all the independent risk factors of their adverse pregnancy outcomes.
维普
万方数据